Auf dieser Seite
ZNTL Zentalis Pharmaceuticals, Inc. - common stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 6, 2026
$2,52
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$1,2152-Wochen-Tief
$6,9552-Wochen-Hoch
Marktkapitalisierung (MRQ)
$181M
P/E
-1.4
EPS
$-1.91
Umsatz
$0
Ihre Abzeichen
52W-Spanne
$1–$7
Analystenbewertung
BUY
Kursziel
$7
P/E
-1.4
ROE
-49.5%
Nettogewinnmarge
·
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
ZNTL Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$2.52
Marktkapitalisierung (MRQ)
$181M
P/E
-1.4
EPS
$-1.91
Umsatz
$0
ROE
-49.5%
52W-Spanne
$1–$7
ZNTL Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$02022-12-31 → 2025-12-31
EPS$-1.912019-12-31 → 2025-12-31
Freier Cashflow$-125M2020-12-31 → 2025-12-31
Nettogewinnmarge·2024-12-31 → 2024-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | ZNTL | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E | -1.45-Jahres-Durchschnitt ≈-6.5 | ≈-6.5 | · | · | |
| K/B (MRQ) | 1.35-Jahres-Durchschnitt ≈1.6 | ≈1.6 | 2.5 | Fairer Wert | |
| Kurs / FCF (TTM) | -1.45-Jahres-Durchschnitt ≈-3.6 | ≈-3.6 | · | · | |
| Kurs / Cashflow (TTM) | -1.45-Jahres-Durchschnitt ≈-3.6 | ≈-3.6 | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 0.85-Jahres-Durchschnitt ≈3.4 | ≈3.4 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | ZNTL | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| ROA | -38.1%5-Jahres-Durchschnitt ≈-43.3% | ≈-43.3% | -49.3% | Spitzenklasse | |
| ROE | -49.5%5-Jahres-Durchschnitt ≈-54.7% | ≈-54.7% | -49.5% | Im Einklang | |
| ROIC | -70.9%5-Jahres-Durchschnitt ≈-62.1% | ≈-62.1% | -129.3% | Spitzenklasse |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | ZNTL | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 4.85-Jahres-Durchschnitt ≈7.3 | ≈7.3 | 5.1 | Im Einklang | |
| Quick Ratio | 1.05-Jahres-Durchschnitt ≈0.7 | ≈0.7 | 2.7 | Geringe Liquidität |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Für diese Kennzahlengruppe sind noch keine Daten verfügbar
Noch nicht genügend Fundamentaldaten vorhanden, um diese Kennzahlengruppe zu berechnen.
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | ZNTL | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.0 | · | 0.1 | Schwach | |
| Receivables Turnover (Forderungsumschlag) | 0.0 | · | 6.2 | Schwach | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$0.00 | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
13.0%
Nächster Bericht
Nov 09, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 4, 2026 | $-0.59 | $-0.50 | -18.1% |
| 31. März 2026 | Mai 12, 2026 | $-0.50 | $-0.49 | -2.9% |
| 31. Dezember 2025 | $-0.50 | $-0.59 | 15.3% | |
| 30. September 2025 | $-0.37 | $-0.54 | 31.3% | |
| 30. Juni 2025 | $-0.37 | $-0.59 | 37.6% | |
| 31. März 2025 | $-0.56 | $-0.65 | 13.9% | |
| 31. Dezember 2024 | $-0.62 | $-0.72 | 13.9% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $0 | $67M | $0 | $0 | |
| R&D Expense | $107M | $168M | $190M | $173M | |
| SG&A Expense | $38M | $87M | $64M | $55M | |
| Operating Expenses | $153M | $259M | $300M | $227M | |
| Operating Income | $-153M | $-191M | $-300M | $-227M | |
| Pretax Income | $-137M | $-166M | $-293M | $-238M | |
| Income Tax | $442.0K | $177.0K | $-601.0K | $-469.0K | |
| Net Income | $-137M | $-166M | $-292M | $-237M | |
| EPS (Basic) | $-1.91 | $-2.33 | $-4.47 | $-4.48 | |
| EPS (Diluted) | $-1.91 | $-2.33 | $-4.47 | $-4.48 | |
| Shares (Basic) | 71,869,000 | 71,080,000 | 65,409,000 | 52,857,000 | |
| Shares (Diluted) | 71,869,000 | 71,080,000 | 65,409,000 | 52,857,000 | |
| EBITDA | $-152M | $-190M | $-298M | $-226M |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Cash & Equivalents | $36M | $34M | $28M | $43M | |
| Receivables | $0 | $5M | $0 | · | |
| Prepaid Expense | $7M | $10M | $14M | $15M | |
| Current Assets | $253M | $386M | $497M | $452M | |
| PP&E (Net) | $3M | $5M | $6M | $8M | |
| PP&E (Gross) | $6M | $9M | $9M | $10M | |
| Accum. Depreciation | $3M | $4M | $3M | $2M | |
| Goodwill | · | $0 | $4M | $4M | |
| Total Assets | $289M | $430M | $552M | $539M | |
| Accounts Payable | $7M | $7M | $15M | $11M | |
| Accrued Liabilities | $29M | $45M | $54M | $45M | |
| Current Liabilities | $37M | $53M | $69M | $57M | |
| Capital Leases | $36M | $40M | $43M | $45M | |
| Deferred Tax | · | · | $0 | $853.0K | |
| Other Non-current Liabilities | $500.0K | $849.0K | $2M | $3M | |
| Total Liabilities | $73M | $93M | $114M | $105M | |
| Common Stock | $69.0K | $71.0K | $70.0K | $59.0K | |
| Paid-in Capital | $1.41B | $1.39B | $1.32B | $1.03B | |
| Retained Earnings | $-1.19B | $-1.05B | $-889M | $-596M | |
| AOCI | $196.0K | $558.0K | $2M | $-1M | |
| Stockholders' Equity | $216M | $337M | $437M | $434M | |
| Liabilities + Equity | $289M | $430M | $552M | $539M | |
| Shares Outstanding | 69,085,980 | 71,282,000 | 70,767,000 | 59,280,000 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| D&A | $739.0K | $1M | $1M | $1M | |
| Stock-based Comp | $21M | $67M | $55M | $47M | |
| Deferred Tax | $51.0K | $-63.0K | $-891.0K | $-778.0K | |
| Restructuring | $8M | $0 | $0 | · | |
| Other Non-cash | $-10M | $-74M | $29M | $26M | |
| Operating Cash Flow | $-125M | $-171M | $-208M | $-164M | |
| CapEx | $0 | $221.0K | $583.0K | $3M | |
| Investing Cash Flow | $132M | $177M | $-44M | $-114M | |
| Stock Issued | $5M | $0 | $236M | $258M | |
| Stock Repurchased | $10M | $0 | $0 | · | |
| Net Stock Activity | $-5M | $0 | $236M | $258M | |
| Financing Cash Flow | $-4M | $108.0K | $237M | $261M | |
| Net Change in Cash | $2M | $6M | $-15M | $-17M | |
| Taxes Paid | $85.0K | · | · | · | |
| Free Cash Flow | $-125M | $-171M | $-208M | $-166M |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating Margin | · | -283.6% | · | · | |
| Net Margin | · | -246.0% | · | · | |
| Pretax Margin | · | -245.7% | · | · | |
| EBITDA Margin | · | -281.6% | · | · | |
| ROA | -38.1% | -33.8% | -53.6% | -47.7% | |
| ROE | -49.5% | -42.8% | -67.1% | -59.3% | |
| ROIC | -70.9% | -56.8% | -68.3% | -52.3% |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Current Ratio | 6.9 | 7.3 | 7.2 | 8.0 | |
| Quick Ratio | 1.0 | 0.7 | 0.4 | 0.8 |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | · | · | |
| Receivables Turnover | 0.0 | 27.0 | · | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Book Value / Share | $3.13 | $4.73 | $6.18 | $7.32 | |
| Revenue / Share | $0.00 | $0.95 | · | · | |
| Cash Flow / Share | $-1.74 | $-2.40 | $-3.18 | $-3.10 | |
| Cash / Share | $0.52 | $0.48 | $0.40 | $0.73 | |
| EPS (TTM) | $-1.91 | $-2.33 | $-4.47 | $-4.48 |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue TTM | $0 | $67M | $0 | $0 | |
| Net Income TTM | $-137M | $-166M | $-292M | $-237M | |
| Market Cap | $93M | $216M | $1.07B | $1.19B | |
| P/E | -0.7 | -1.3 | -3.4 | -4.5 | |
| P/S | · | 3.2 | · | · | |
| P/B | 0.4 | 0.6 | 2.5 | 2.8 | |
| P / Tangible Book | 0.4 | 0.6 | 2.5 | 2.8 | |
| P / Cash Flow | -0.7 | -1.3 | -5.2 | -7.3 | |
| P / FCF | -0.7 | -1.3 | -5.1 | -7.2 | |
| Earnings Yield | -141.5% | -76.9% | -29.5% | -22.2% |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $0 | $0 | $0 | $0 | $27M | $0 | $0 | $41M | $0 | $0 | $0 | $0 | |
| R&D Expense | $35M | $29M | $29M | $23M | $28M | $27M | $33M | $37M | $48M | $50M | $52M | $47M | $43M | $49M | |
| SG&A Expense | $9M | $9M | $8M | $11M | $8M | $11M | $40M | $15M | $17M | $16M | $16M | $16M | $16M | $16M | |
| Operating Expenses | $44M | $38M | $37M | $34M | $36M | $46M | $77M | $51M | $65M | $65M | $68M | $63M | $104M | $65M | |
| Operating Income | $-44M | $-38M | $-37M | $-34M | $-36M | $-46M | $-50M | $-51M | $-65M | $-25M | $-68M | $-63M | $-104M | $-65M | |
| Pretax Income | $-42M | $-35M | $-35M | $-27M | $-27M | $-48M | $-48M | $-40M | $-88M | $10M | $-77M | $-56M | $-99M | $-61M | |
| Income Tax | $138.0K | $120.0K | $442.0K | $0 | $0 | $0 | $-205.0K | $-27.0K | $266.0K | $143.0K | $-135.0K | $31.0K | $-605.0K | $108.0K | |
| Net Income | $-42M | $-35M | $-35M | $-27M | $-27M | $-48M | $-47M | $-40M | $-88M | $10M | $-61M | $-56M | $-113M | $-63M | |
| EPS (Basic) | $-0.59 | $-0.50 | $-0.50 | $-0.37 | $-0.37 | $-0.67 | $-0.67 | $-0.56 | $-1.24 | $0.14 | $-0.76 | $-0.79 | $-1.85 | $-1.07 | |
| EPS (Diluted) | $-0.59 | $-0.50 | $-0.50 | $-0.37 | $-0.37 | $-0.67 | $-0.67 | $-0.56 | $-1.24 | $0.14 | $-0.76 | $-0.79 | $-1.85 | $-1.07 | |
| Shares (Basic) | 71,326,000 | 70,264,000 | · | 72,139,000 | 71,992,000 | 71,678,000 | · | 71,111,000 | 71,040,000 | 70,898,000 | · | 70,612,000 | 60,790,000 | 59,277,000 | |
| Shares (Diluted) | 71,326,000 | 70,264,000 | · | 72,139,000 | 71,992,000 | 71,678,000 | · | 71,111,000 | 71,040,000 | 71,192,000 | · | 70,612,000 | 60,790,000 | 59,277,000 | |
| EBITDA | $-44M | $-38M | · | $-34M | $-36M | $-45M | · | $-51M | $-65M | $-24M | · | $-62M | $-104M | $-65M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $25M | $32M | $36M | $39M | $38M | $42M | $34M | $41M | $37M | $38M | $28M | $111M | $267M | $36M | |
| Receivables | · | · | $0 | $0 | $0 | $0 | $5M | · | · | · | · | · | · | · | |
| Prepaid Expense | $7M | $6M | $7M | $8M | $8M | $10M | $10M | $9M | $13M | $15M | · | $12M | $11M | $18M | |
| Current Assets | $181M | $218M | $253M | $288M | $312M | $343M | $386M | $400M | $440M | $504M | · | $528M | $564M | $410M | |
| PP&E (Net) | $2M | $3M | $3M | $3M | $3M | $3M | $5M | $5M | $5M | $6M | · | $6M | $7M | $7M | |
| PP&E (Gross) | $6M | $6M | $6M | $6M | $6M | $6M | $9M | $9M | $9M | $9M | · | $10M | $9M | $10M | |
| Accum. Depreciation | $3M | $3M | $3M | $3M | $3M | $2M | $4M | $4M | $4M | $3M | · | $3M | $3M | $3M | |
| Goodwill | · | · | · | · | · | · | · | $4M | $4M | $4M | · | $4M | $4M | $4M | |
| Total Assets | $215M | $253M | $289M | $327M | $352M | $384M | $430M | $451M | $492M | $557M | · | $586M | $621M | $489M | |
| Accounts Payable | $8M | $7M | $7M | $7M | $4M | $8M | $7M | $8M | $20M | $11M | · | $14M | $12M | $13M | |
| Accrued Liabilities | $29M | $28M | $29M | $30M | $35M | $42M | $45M | $47M | $46M | $44M | · | $45M | $39M | $44M | |
| Current Liabilities | $38M | $35M | $37M | $37M | $39M | $49M | $53M | $55M | $67M | $55M | · | $59M | $52M | $56M | |
| Capital Leases | $34M | $35M | $36M | $37M | $38M | $39M | $40M | $40M | $41M | $43M | · | $43M | $44M | $45M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $756.0K | |
| Other Non-current Liabilities | $500.0K | $500.0K | $500.0K | $500.0K | $500.0K | $558.0K | $849.0K | $996.0K | $1M | $1M | · | $2M | $2M | $2M | |
| Total Liabilities | $72M | $70M | $73M | $74M | $77M | $89M | $93M | $96M | $109M | $99M | · | $104M | $98M | $104M | |
| Common Stock | $72.0K | $71.0K | $69.0K | $72.0K | $72.0K | $72.0K | $71.0K | $71.0K | $71.0K | $70.0K | · | $70.0K | $70.0K | $59.0K | |
| Paid-in Capital | $1.41B | $1.41B | $1.41B | $1.41B | $1.40B | $1.40B | $1.39B | $1.36B | $1.35B | $1.34B | · | $1.31B | $1.30B | $1.05B | |
| Retained Earnings | $-1.27B | $-1.23B | $-1.19B | $-1.16B | $-1.13B | $-1.10B | $-1.05B | $-1.01B | $-967M | $-878M | · | $-828M | $-772M | $-660M | |
| AOCI | $-78.0K | $-50.0K | $196.0K | $186.0K | $59.0K | $358.0K | $558.0K | $2M | $140.0K | $773.0K | · | $-359.0K | $-338.0K | $-556.0K | |
| Stockholders' Equity | $144M | $183M | $216M | $253M | $274M | $295M | $337M | $354M | $383M | $459M | · | $482M | $523M | $385M | |
| Liabilities + Equity | $215M | $253M | $289M | $327M | $352M | $384M | $430M | $451M | $492M | $557M | · | $586M | $621M | $489M | |
| Shares Outstanding | 71,668,568 | 71,156,113 | 69,085,980 | 72,245,529 | 72,135,453 | 71,950,683 | 71,282,400 | 71,149,666 | 71,106,719 | 71,011,982 | 70,767,000 | 70,640,684 | 70,603,663 | 59,442,342 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $152.0K | $151.0K | $157.0K | $160.0K | $160.0K | $262.0K | $317.0K | $321.0K | $327.0K | $324.0K | $337.0K | $348.0K | $344.0K | $360.0K | |
| Stock-based Comp | $3M | $3M | $3M | $5M | $6M | $6M | $31M | $10M | $13M | $13M | $14M | $14M | $13M | $14M | |
| Restructuring | $0 | $0 | $0 | $0 | $0 | $8M | $0 | $0 | $0 | $0 | · | · | · | · | |
| Other Non-cash | · | $-952.0K | · | · | · | $9M | · | · | · | $-75M | · | · | · | $-157.0K | |
| Operating Cash Flow | $-37M | $-33M | $-31M | $-27M | $-35M | $-33M | $-40M | $-44M | $-35M | $-52M | $-41M | $-39M | $-79M | $-49M | |
| CapEx | $0 | $34.0K | $0 | $0 | $0 | $0 | $0 | $0 | $181.0K | $40.0K | $173.0K | $91.0K | $319.0K | $0 | |
| Investing Cash Flow | $30M | $30M | $32M | $28M | $30M | $40M | $32M | $48M | $34M | $62M | $-42M | $-117M | $73M | $42M | |
| Stock Issued | · | · | · | · | · | · | $0 | $0 | · | · | $0 | $0 | · | · | |
| Financing Cash Flow | $65.0K | $-1M | $-5M | $115.0K | $0 | $189.0K | $0 | $92.0K | $9.0K | $7.0K | $0 | $309.0K | $237M | $373.0K | |
| Net Change in Cash | $-7M | $-4M | $-3M | $1M | $-4M | $8M | $-7M | $4M | $-640.0K | $10M | $-83M | $-156M | $230M | $-7M | |
| Free Cash Flow | · | $-33M | · | · | · | $-33M | · | · | · | $-52M | · | · | · | $-49M |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | · | · | · | · | -61.1% | · | · | · | · | |
| Net Margin | · | · | · | · | · | · | · | · | · | 24.8% | · | · | · | · | |
| Pretax Margin | · | · | · | · | · | · | · | · | · | 25.1% | · | · | · | · | |
| EBITDA Margin | · | · | · | · | · | · | · | · | · | -60.3% | · | · | · | · | |
| ROA | -14.9% | -11.1% | · | -6.9% | -6.4% | -10.3% | · | -7.8% | -15.9% | 1.9% | · | -10.0% | -18.9% | -14.1% | |
| ROE | -20.2% | -14.8% | · | -8.8% | -8.2% | -12.8% | · | -9.6% | -19.5% | 2.4% | · | -12.2% | -22.6% | -18.0% | |
| ROIC | -31.0% | -20.8% | · | -13.3% | -13.1% | -15.4% | · | -14.5% | -17.1% | -5.3% | · | -13.0% | -19.7% | -16.9% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.8 | 6.2 | · | 7.8 | 8.0 | 6.9 | · | 7.3 | 6.6 | 9.2 | · | 9.0 | 10.9 | 7.3 | |
| Quick Ratio | 0.7 | 0.9 | · | 1.1 | 1.0 | 0.8 | · | 0.8 | 0.6 | 0.7 | · | 1.9 | 5.2 | 0.6 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.1 | · | · | · | · | |
| Receivables Turnover | · | · | · | 0.0 | 0.0 | 0.0 | · | · | · | · | · | · | · | · |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.00 | $2.57 | · | $3.50 | $3.81 | $4.11 | · | $4.98 | $5.38 | $6.46 | · | $6.82 | $7.41 | $6.49 | |
| Revenue / Share | · | · | · | $0.00 | $0.00 | $0.00 | · | $0.00 | $0.00 | $0.57 | · | · | · | · | |
| Cash Flow / Share | · | $-0.47 | · | · | · | $-0.46 | · | · | · | $-0.73 | · | · | · | $-0.83 | |
| Cash / Share | $0.35 | $0.45 | · | $0.54 | $0.52 | $0.58 | · | $0.58 | $0.52 | $0.53 | · | $1.57 | $3.78 | $0.61 | |
| EPS (TTM) | $-1.96 | $-1.74 | · | $-2.08 | $-2.27 | $-3.14 | · | $-2.42 | $-2.65 | $-3.26 | · | $-4.58 | $-4.75 | $-4.24 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | · | $27M | $27M | $27M | · | $41M | $41M | $41M | · | · | · | · | |
| Net Income TTM | $-140M | $-124M | · | $-149M | $-163M | $-224M | · | $-179M | $-195M | $-219M | · | $-286M | $-285M | $-241M | |
| Market Cap | $348M | $167M | · | $109M | $84M | $114M | · | $262M | $291M | $1.12B | · | $1.42B | $1.99B | $1.02B | |
| P/E | -2.5 | -1.3 | · | -0.7 | -0.5 | -0.5 | · | -1.5 | -1.5 | -4.8 | · | -4.4 | -5.9 | -4.1 | |
| P/S | · | · | · | 4.1 | 3.1 | 4.3 | · | 6.5 | 7.2 | 27.6 | · | · | · | · | |
| P/B | 2.4 | 0.9 | · | 0.4 | 0.3 | 0.4 | · | 0.7 | 0.8 | 2.4 | · | 2.9 | 3.8 | 2.7 | |
| P / Tangible Book | 2.4 | 0.9 | · | 0.4 | 0.3 | 0.4 | · | 0.7 | 0.8 | 2.5 | · | 3.0 | 3.8 | 2.7 | |
| P / Cash Flow | · | -5.1 | · | · | · | -3.5 | · | · | · | -21.5 | · | · | · | -20.7 | |
| Earnings Yield | -40.4% | -74.4% | · | -137.8% | -195.7% | -197.5% | · | -65.8% | -64.8% | -20.7% | · | -22.8% | -16.8% | -24.6% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $0 | $67M | $0 | $0 | · |
| Betriebsgewinnmarge % | · | -283.6% | · | · | · |
| Nettoergebnis | $-137M | $-166M | $-292M | $-237M | $-159M |
| Verwässerte EPS | $-1.91 | $-2.33 | $-4.47 | $-4.48 | $-3.72 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Liquiditätsgrad | 6.9 | 7.3 | 7.2 | 8.0 | · |
| Quick Ratio | 1.0 | 0.7 | 0.4 | 0.8 | · |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-125M | $-171M | $-208M | $-166M | · |
Institutionelle Eigentümer (13F) 127 Einreicher · $225.0M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
127
Gehaltener Wert
$225.0M
Neue Positionen
36
Geschlossene Positionen
19
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 36 (+4 vs. Vorquartal) | 19 (+10 vs. Vorquartal) | 31 (+1 vs. Vorquartal) | 33 (+7 vs. Vorquartal) | +4.1M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| 5AM Venture Management, LLC | $19.147.378 | 3.947.913 | 8,51% | Aktien |
| BlackRock, Inc. | $18.204.597 | 3.753.525 | 8,09% | Aktien |
| Squadron Capital Management LLC | $17.945.000 | 3.700.000 | 7,98% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $14.670.940 | 3.024.936 | 6,52% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $13.752.995 | 2.835.669 | 6,11% | Aktien |
| CITADEL ADVISORS LLC | $11.147.254 | 2.298.403 | 4,95% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $7.804.028 | 1.609.078 | 3,47% | Aktien |
| Opaleye Management Inc. | $6.851.382 | 1.412.656 | 3,05% | Aktien |
| ORBIMED ADVISORS LLC | $6.744.294 | 1.390.576 | 3,00% | Aktien |
| Decheng Capital LLC | $6.418.136 | 1.323.327 | 2,85% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $6.229.699 | 1.284.117 | 2,77% | Aktien |
| BANK OF AMERICA CORP /DE/ | $5.406.053 | 1.114.650 | 2,40% | Aktien |
| Ishara Investments LP | $4.971.250 | 1.025.000 | 2,21% | Aktien |
| PRIMECAP MANAGEMENT CO/CA/ | $4.643.487 | 957.420 | 2,06% | Aktien |
| Soleus Capital Management, L.P. | $4.607.500 | 950.000 | 2,05% | Aktien |
| STATE STREET CORP | $4.303.968 | 887.416 | 1,91% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $3.921.458 | 808.548 | 1,74% | Aktien |
| VANGUARD GROUP INC | $3.855.047 | 2.855.590 | 1,71% | Aktien |
| Pfizer Inc | $3.853.489 | 953.834 | 1,71% | Aktien |
| Connor, Clark & Lunn Investment Management Ltd. | $3.676.460 | 758.033 | 1,63% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $3.221.763 | 664.281 | 1,43% | Aktien |
| ADAR1 Capital Management, LLC | $3.165.838 | 652.750 | 1,41% | Aktien |
| MARSHALL WACE, LLP | $2.868.644 | 591.473 | 1,28% | Aktien |
| Qube Research & Technologies Ltd | $2.787.809 | 574.806 | 1,24% | Aktien |
| D. E. Shaw & Co., Inc. | $2.650.845 | 546.566 | 1,18% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $2.630.116 | 542.852 | 1,17% | Aktien |
| MORGAN STANLEY | $2.285.563 | 471.250 | 1,02% | Aktien |
| Squadron Capital Management LLC | $2.066.100 | 426.000 | 0,92% | Kaufoption |
| TWO SIGMA ADVISERS, LP | $2.002.725 | 1.483.500 | 0,89% | Aktien |
| NORTHERN TRUST CORP | $1.883.251 | 388.299 | 0,84% | Aktien |
| GOLDMAN SACHS GROUP INC | $1.806.936 | 372.564 | 0,80% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $1.634.159 | 336.940 | 0,73% | Aktien |
| FMR LLC | $1.504.780 | 310.264 | 0,67% | Aktien |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | $1.451.844 | 961.486 | 0,65% | Aktien |
| Seven Fleet Capital Management LP | $1.451.432 | 317.600 | 0,65% | Aktien |
| UBS Group AG | $1.442.283 | 297.378 | 0,64% | Aktien |
| XTX Topco Ltd | $1.405.011 | 289.693 | 0,62% | Aktien |
| Creative Planning | $1.382.250 | 285.000 | 0,61% | Aktien |
| SEI INVESTMENTS CO | $1.241.983 | 256.079 | 0,55% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.043.298 | 215.113 | 0,46% | Aktien |
| Peapod Lane Capital LLC | $983.890 | 202.864 | 0,44% | Aktien |
| CDC Financial, Inc. | $862.146 | 177.762 | 0,38% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $833.768 | 171.911 | 0,37% | Aktien |
| Invesco Ltd. | $784.037 | 161.657 | 0,35% | Aktien |
| Stonepine Capital Management, LLC | $783.678 | 161.583 | 0,35% | Aktien |
| BARCLAYS PLC | $770.452 | 158.856 | 0,34% | Aktien |
| Anfield Capital Management, LLC | $642.367 | 274.516 | 0,29% | Aktien |
| Informed Momentum Co LLC | $615.286 | 126.863 | 0,27% | Aktien |
| Quarry LP | $606.803 | 125.114 | 0,27% | Aktien |
| Bank of New York Mellon Corp | $592.030 | 122.068 | 0,26% | Aktien |
Aktivisten & 5%+-Eigentümer 2 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Matrix Capital Management Company, LP, David E. Goel ×2 Einreichungen | 2. Januar 2026 | 0,00% | Änderung | · | SEC |
| Matrix Capital Management Company LP, David E. Goel ×2 Einreichungen | 20. Juni 2023 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 23 Insider · 16 Führungskräfte · 10 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Julia Marie Eastland | CEO & President | 9. Februar 2026 S | 79.133 | 0 | 2 | $-21.239 |
| Kimberly Blackwell | Chief Executive Officer | 1. Februar 2024 A | 484.145 | 0 | 0 | $0 |
| Anthony Y Sun | President & CEO | 5. April 2022 S | 1.175.589 | 0 | 0 | $0 |
| Cam Gallagher | President, Interim CFO | 31. Mai 2024 S | 633.680 | 0 | 0 | $0 |
| Melissa B, Epperly | Chief Financial Officer | 12. Februar 2024 S | 451.449 | 0 | 0 | $0 |
| Iris Roth | Chief Operating Officer | 1. März 2023 A | 52.500 | 0 | 0 | $0 |
| Ingmar Bruns | Chief Medical Officer | 30. September 2026 A | 43.059 | 0 | 2 | $-7.999 |
| Vincent Vultaggio | PAO and PFO | 10. Februar 2026 S | 146.506 | 0 | 5 | $-105.418 |
| James B Bucher | Chief Legal Officer | 8. Januar 2026 A | · | 0 | 0 | $0 |
| Andrea Paul | Chief Legal Officer | 3. Februar 2025 A | 1.070.784 | 0 | 0 | $0 |
| Mark Lackner | Chief Scientific Officer | 3. Februar 2025 A | 512.856 | 0 | 0 | $0 |
| Diana Hausman | Chief Medical Officer | 9. Mai 2024 S | 373.876 | 0 | 0 | $0 |
| Kevin D. Bunker | Chief Scientific Officer | 20. Dezember 2023 G | 834.931 | 0 | 0 | $0 |
| Carrie Brownstein | Chief Medical Officer | 4. Oktober 2023 S | 105.685 | 0 | 0 | $0 |
| Alexis Pinto | Chief Legal Officer | 10. Februar 2022 A | 22.240 | 0 | 0 | $0 |
| Dimitris Voliotis | SVP, Clinical Development | 10. Februar 2022 A | 15.978 | 0 | 0 | $0 |
| Enoch Kariuki | Direktor | 16. Juni 2026 A | 194.465 | 0 | 0 | $0 |
| Jan Skvarka | Direktor | 16. Juni 2026 A | 264.254 | 0 | 0 | $0 |
| David Michael Johnson | Direktor | 16. Juni 2026 A | 307.521 | 0 | 0 | $0 |
| Luke Nathaniel Walker | Direktor | 16. Juni 2026 A | 201.384 | 0 | 0 | $0 |
| Scott Dunseth Myers | Direktor | 16. Juni 2026 A | 395.895 | 0 | 0 | $0 |
| Shannon Campbell | Direktor | 26. Mai 2026 A | 114.200 | 0 | 0 | $0 |
| Recurium Equity, LLC | 10%-Eigentümer | 28. Oktober 2020 J | 14.990 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 18 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| IWC · iShares Trust | 0,04% | 170.201 SH | 11. September 2026 | Täglich |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,02% | 21.344 SH | 2. Oktober 2026 | Täglich |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,02% | 43.495 SH | 19. August 2026 | Täglich |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,01% | 111.531 SH | 2. Oktober 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 289.218 SH | 19. August 2026 | Täglich |
| RSSL · Global X Funds | 0,01% | 23.883 NS | 31. Juli 2026 | N-PORT |
| IWM · iShares Trust | 0,01% | 1.282.558 SH | 11. September 2026 | Täglich |
| DFAS · Dimensional ETF Trust | 0,00% | 154.468 NS | 31. Juli 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,00% | 4.890 NS | 31. Juli 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 10.234 NS | 31. Juli 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 10.252 NS | 31. Juli 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 8.219 NS | 31. Juli 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 9.284 NS | 31. Juli 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 575.846 SH | 19. August 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 2.187.299 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 4.227 SH | 19. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,00% | 151.148 SH | 19. August 2026 | Täglich |
| IWN · iShares Trust | · | 483.199 SH | 11. September 2026 | Täglich |
ZNTL Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 16 Analysten
KAUF
Median-Ziel
$6.00
+138,1%
4 25,0%
Starker Kauf
6 37,5%
Kauf
6 37,5%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
9 Analysten · 2026-09-29Mittelwert-Ziel $6.89 +173,4%
← Unter allen Zielen
Aktueller Preis $2.52
Tief$4.00
Mittelwert$6.89
Hoch$10.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| ZNTL | $93M | -0.7 | · | · | -49.5% | · |
| ARCT | $174M | -2.6 | -46.1% | -80.2% | -29.6% | · |
| INDP | $6M | -0.1 | · | · | -2820.8% | · |
| CCCC | $185M | -1.5 | 1.0% | -292.1% | -48.8% | · |
| FENC | $263M | -22.6 | -6.1% | -21.8% | -69.6% | · |
| OCGN | $422M | -5.6 | 8.8% | -1537.4% | 1488.8% | · |
| SRZN | · | · | · | · | · | · |
| CABA | $220M | -1.0 | · | · | -115.5% | · |
| ARTV | · | -1.3 | -99.2% | · | · | · |
| CYPH | $97M | 16.6 | · | · | 6.1% | · |
| EBS | $644M | 13.3 | -28.8% | 7.1% | 9.9% | · |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 6, 2026